Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 120,109

Document Document Title
WO/2016/168768A3
The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, ...  
WO/2016/168598A1
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6 and HDAC11, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerativ...  
WO/2016/165014A1
The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal ad...  
WO/2016/167372A1
Provided is a method for producing cerebral cortex neurons from pluripotent stem cells. Provided is a method for producing cerebral cortex neurons from pluripotent stem cells, including: (i) a step for carrying out suspension culture of ...  
WO/2016/164218A1
The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of t...  
WO/2016/164685A1
Neuroprotective compositions, methods of making the same, and methods of using the same, are disclosed.  
WO/2016/162706A1
Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes and thereof, and the medicinal ...  
WO/2016/162246A1
The present invention relates to the use of glucomoringin (GMG) and of the corresponding isothiocyanate derivative glucomoringin des-thioglucoside (GMG-ITC) as modulators of peripheral pain with specific reference to that linked with dia...  
WO/2016/164763A1
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...  
WO/2016/164295A3
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1. Formula (I).  
WO/2016/164763A8
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...  
WO/2016/162821A3
This invention relates to a medicament. It also relates to a nutritional supplement. More particularly it relates to a medicament and to a nutritional supplement, which are extracts from a plant or a combination of plants. The extract ac...  
WO/2016/164768A1
As disclosed herein, stapled peptides targeting the interaction interface between proteins that maintain the integrity of Wiskott-Aldrich syndrome protein family member 3 (WASF3) leads to destabilization of WASF3 and suppression of invas...  
WO/2016/163912A1
The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth f...  
WO/2016/162506A1
The present invention relates to a composition that comprises the peptide QBP for use in the inhibition of memory consolidation, after a trauma, more preferably in Post-Traumatic Stress Disorder or related diseases.  
WO/2016/164521A1
The present invention relates to the treatment and prevention of movement disorders with the administration of one or more propionyl-CoA precursors.  
WO/2016/163886A3
The present invention relates to the use of taurine or an analog thereof and/or albumin, for use in the treatment of nerve cell damage. In particular, taurine or a metabolite or precursor thereof and/or albumin may be administered for th...  
WO/2016/162870A1
Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Va...  
WO/2016/164642A1
Provided herein are compositions and methods for the viral gene therapy (e.g., AAV-directed gene therapy) of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.  
WO/2016/162706A9
Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes and thereof, and the medicinal ...  
WO/2016/162821A2
This invention relates to a medicament. It also relates to a nutritional supplement. More particularly it relates to a medicament and to a nutritional supplement, which are extracts from a plant or a combination of plants. The extract ac...  
WO/2016/161055A2
In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. ...  
WO/2016/161388A1
Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distrib...  
WO/2016/160574A2
The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl- pyrrolidine-2-carboxamide compounds and phar...  
WO/2016/160715A1
The present invention provides a method of treating a patient suffering from addiction, having the steps of administering to the patient a controlled release composition comprising an opioid antagonist; and coaching the patient. This sim...  
WO/2016/161343A2
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/160881A1
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and...  
WO/2016/161055A3
In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. ...  
WO/2016/155673A1
The present application provides uses of hydroxy-substituted benzophenone compound in the preparation of drugs for preventing and treating viral infection and in the preparation of tumor drugs.  
WO/2016/161374A1
This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.  
WO/2016/158810A1
This agent for the prevention and/or treatment of conditions associated with RAGE/ligand interactions, containing as an active ingredient a compound represented by formula (I): (in the formula, each of the symbols is defined as in the de...  
WO/2016/156527A1
The subject matter of the invention is the use, as a medicament or medical nutrition product in humans, for the treatment of pathological dysbiosis and/or for the prevention or treatment of at least one derived metabolic disease chosen f...  
WO/2016/156396A1
Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurodegenerative, psychiatric and neuropsychiatric disorders, and also as anti- itch, anti-addiction, anti-inflammatory, anti...  
WO/2016/155661A1
Provided is a compound capable of being used to treat diseases caused by cell proliferation and/or angiogenesis or diseases associated with or accompanied by the cell proliferation and/or the angiogenesis.  
WO/2016/155545A1
Disclosed are a sulfamyl-containing 1,2,5-oxadiazole derivative, a preparation method therefor, and a use thereof in pharmaceuticals. Specifically disclosed are a sulfamyl-containing 1,2,5-oxadiazole derivative of generic formula (I), a ...  
WO/2016/160542A1
The invention provides compositions and methods for treating seizure disorders such as epilepsy in humans and animals using, the combination of a non-barbiturate anti-epileptic drug (NAED), phytocannabinoid cannabidiol (CBD); and a lipop...  
WO/2016/159082A1
The purpose of the present invention is to provide a novel compound having ACC2 inhibition activity and to provide a pharmaceutical composition containing the compound. Provided are a compound represented by formula (I) and a pharmaceuti...  
WO/2016/159335A1
Provided is a means for reducing adverse effects of a high glucose concentration on the living body. Provided are: a preparation for protecting glucose-sensitive cells from glucose toxicity caused by a high glucose concentration, the pre...  
WO/2016/154682A1
The present invention relates to methods for predicting a risk of cognitive deterioration, monitoring progression of cognitive deterioration and diagnosing cognitive deterioration in a patient. The present invention further relates to me...  
WO/2016/157053A1
A pharmaceutical composition or dietary supplement effective in the treatment of neuropathies and/or neuropathic pain is described, which comprises, as the active ingredients, the combination of curcumin, N-acetyl-L-carnitine and alpha-l...  
WO/2016/155888A1
The present invention relates to novel compounds of the formula I, methods for their preparation and their use for treatment of diseases. The invention discloses the synthesis of levodopa (L-DOPA) esters by coupling polyhydroxy compounds...  
WO/2016/160885A1
The invention describes membrane permeable creatine phosphate analog prodrugs, pharmaceutical compositions comprising membrane permeable creatine phosphate analog prodrugs, and methods of treating diseases such as ischemia, heart failure...  
WO/2016/159695A1
The present invention relates to a composition for preventing or treating an autoimmune disease, containing Ssu72 as an active ingredient. According to the present invention, Ssu72 has an effect of effectively inhibiting STAT3 activity, ...  
WO/2016/161343A3
The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; an...  
WO/2016/159256A1
A pharmaceutical composition for the treatment or prevention of neurodegenerative diseases, the pharmaceutical composition having as an active ingredient an RXR agonist that is a compound represented by formula (1) or formula (2). This p...  
WO/2016/158956A1
Provided is a compound having an MAGL inhibitory effect, and expected to be useful as an agent for the prevention or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotroph...  
WO/2016/160574A3
The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl- pyrrolidine-2-carboxamide compounds and phar...  
WO/2016/154683A1
A method of managing pain in an individual including the following steps: providing an individual in need of pain management; administering an anti-P2X7 receptor antibody to the individual; thereby managing pain in the individual.  
WO/2016/151265A1
The invention relates to a combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1, 3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione, of the following formula [I], or one of the acid addition salts or pharmaceutically ac...  
WO/2016/150936A1
The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present - but structurally different - components, ...  

Matches 351 - 400 out of 120,109